Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Claritas Pharmaceuticals Inc. (V:CLAS)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for CLAS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 20, 2022 07:48 ET
IIROC Trading Halt - CLAS
VANCOUVER, BC, July 20, 2022 /CNW/ - The following issues have been halted by IIROC:
Read full article
Apr 26, 2022 12:10 ET
IIROC Trading Halt - CLAS.WT.B
VANCOUVER, BC, April 26, 2022 /CNW/ - The following issues have been halted by IIROC:
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
2.78
3.45
Price to Book - most recent quarter
--
2.66
2.04
Price to Cash Flow per share - TTM
--
6.39
10.35
Price to Free Cash Flow per share - TTM
--
24.85
12.34
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20242880
Feb 29, 20242880
Feb 15, 20242880
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company's products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

See business summary

 

Twitter

Search (past week) for $CLAS.CA CLAS.V

  • No tweets found